Cisplain, 5-Fluorouracil (5-FU), and Leucovorin(LV) in Refractory Gastric Cancer Patients

陳 榮楷(Wing-K. Chan), 吳 秋文(Chu W. Wu), 林 增熙(Tzeng H. Lin), 季 匡華(Kwan H. Chi), 趙 毅(Yee Chao), 黃 以信(Y. S. Huang), 吳 銘芳(Ming F. Wu), 陳 育民(Yue M. Chen), 劉 敏(Ming Liu), 彭汪 嘉康(Jacqueline Whang-Peng), 李 壽東(Shou D. Lee), 雷 永耀(Wing Y. Lui)

Research output: Contribution to journalArticle

Abstract

Background: Patients with advanced gastric cancer who failed first line chemotherapy have a poor prognosis. However, there are few effective treatments against refractory gastric cancer. Based on encouraging results of cisplatin, 5-Fluorouracil and leucovorin (PFL) in patients with gastric cancer, nasopharyngeal cancer and other cancers, we conducted this pilot study of test PEL chemotherapy in patients with refractory advanced gastric cancer.
Method: Patients with measurable advanced gastric cancer, refractory to prior chemotherapy were eligible for study. Cisplatin 20mg/m^2/d, 5-FU 800mg/m^2/d and leucovorin 90mg/m^2/d were administered simultaneously by continuous 96-hour intravenous infusion every three weeks. Patients were evaluated for response, survival, and toxicity.
Results: Twenty patients were studied. Fifteen patients were evaluable. There were no complete response. Partial response was achieved in 4 patients. The response rate of PFL chemotherapy were 27%. The overall toxicity was tolerable. Mucositis and leukopenia were the major toxicities. No grade IV toxicities or treatment-related deaths occurred.
Conclusions: PEL chemotherpy is safe and may be effective in the treatment of refractory gastric cancer patients. Further clinical studies of PFL in gastric cancer may be indicated.
Original languageEnglish
Pages (from-to)255-262
Number of pages8
Journal放射治療與腫瘤學
Volume1
Issue number3
DOIs
Publication statusPublished - 1994
Externally publishedYes

Fingerprint

Leucovorin
Fluorouracil
Stomach Neoplasms
Drug Therapy
Cisplatin
Nasopharyngeal Neoplasms
Mucositis
Leukopenia
Intravenous Infusions
Therapeutics
Survival

Keywords

  • Cisplatin
  • 5-Fluorouracil
  • Leucovorin頑固性胃癌
  • Refractory Gastric Cancer
  • Fluorouracil
  • Leucovorin

Cite this

陳榮楷(Wing-K C, 吳秋文(Chu W W, 林增熙(Tzeng H L, 季匡華(Kwan H C, 趙毅(Yee C, 黃以信(Y S H, ... 雷永耀(Wing Y L (1994). Cisplain, 5-Fluorouracil (5-FU), and Leucovorin(LV) in Refractory Gastric Cancer Patients. 放射治療與腫瘤學, 1(3), 255-262. https://doi.org/10.6316/TRO/199401

Cisplain, 5-Fluorouracil (5-FU), and Leucovorin(LV) in Refractory Gastric Cancer Patients. / 陳榮楷(Wing-K. Chan); 吳秋文(Chu W. Wu); 林增熙(Tzeng H. Lin); 季匡華(Kwan H. Chi); 趙毅(Yee Chao); 黃以信(Y. S. Huang); 吳銘芳(Ming F. Wu); 陳育民(Yue M. Chen); 劉敏(Ming Liu); 彭汪嘉康(Jacqueline Whang-Peng); 李壽東(Shou D. Lee); 雷永耀(Wing Y. Lui).

In: 放射治療與腫瘤學, Vol. 1, No. 3, 1994, p. 255-262.

Research output: Contribution to journalArticle

陳榮楷(Wing-KC, 吳秋文(ChuWW, 林增熙(TzengHL, 季匡華(KwanHC, 趙毅(YeeC, 黃以信(YSH, 吳銘芳(MingFW, 陳育民(YueMC, 劉敏(MingL, 彭汪嘉康(JacquelineW-P, 李壽東(ShouDL & 雷永耀(WingYL 1994, 'Cisplain, 5-Fluorouracil (5-FU), and Leucovorin(LV) in Refractory Gastric Cancer Patients', 放射治療與腫瘤學, vol. 1, no. 3, pp. 255-262. https://doi.org/10.6316/TRO/199401
陳榮楷(Wing-KC, 吳秋文(ChuWW, 林增熙(TzengHL, 季匡華(KwanHC, 趙毅(YeeC, 黃以信(YSH et al. Cisplain, 5-Fluorouracil (5-FU), and Leucovorin(LV) in Refractory Gastric Cancer Patients. 放射治療與腫瘤學. 1994;1(3):255-262. https://doi.org/10.6316/TRO/199401
陳榮楷(Wing-K. Chan) ; 吳秋文(Chu W. Wu) ; 林增熙(Tzeng H. Lin) ; 季匡華(Kwan H. Chi) ; 趙毅(Yee Chao) ; 黃以信(Y. S. Huang) ; 吳銘芳(Ming F. Wu) ; 陳育民(Yue M. Chen) ; 劉敏(Ming Liu) ; 彭汪嘉康(Jacqueline Whang-Peng) ; 李壽東(Shou D. Lee) ; 雷永耀(Wing Y. Lui). / Cisplain, 5-Fluorouracil (5-FU), and Leucovorin(LV) in Refractory Gastric Cancer Patients. In: 放射治療與腫瘤學. 1994 ; Vol. 1, No. 3. pp. 255-262.
@article{bde3db3a0d6746a9ab3ea37a1dfbd659,
title = "Cisplain, 5-Fluorouracil (5-FU), and Leucovorin(LV) in Refractory Gastric Cancer Patients",
abstract = "Background: Patients with advanced gastric cancer who failed first line chemotherapy have a poor prognosis. However, there are few effective treatments against refractory gastric cancer. Based on encouraging results of cisplatin, 5-Fluorouracil and leucovorin (PFL) in patients with gastric cancer, nasopharyngeal cancer and other cancers, we conducted this pilot study of test PEL chemotherapy in patients with refractory advanced gastric cancer.Method: Patients with measurable advanced gastric cancer, refractory to prior chemotherapy were eligible for study. Cisplatin 20mg/m^2/d, 5-FU 800mg/m^2/d and leucovorin 90mg/m^2/d were administered simultaneously by continuous 96-hour intravenous infusion every three weeks. Patients were evaluated for response, survival, and toxicity.Results: Twenty patients were studied. Fifteen patients were evaluable. There were no complete response. Partial response was achieved in 4 patients. The response rate of PFL chemotherapy were 27{\%}. The overall toxicity was tolerable. Mucositis and leukopenia were the major toxicities. No grade IV toxicities or treatment-related deaths occurred.Conclusions: PEL chemotherpy is safe and may be effective in the treatment of refractory gastric cancer patients. Further clinical studies of PFL in gastric cancer may be indicated.",
keywords = "Cisplatin, 5-Fluorouracil, Leucovorin頑固性胃癌, Refractory Gastric Cancer, Fluorouracil, Leucovorin",
author = "陳, {榮楷(Wing-K. Chan)} and 吳, {秋文(Chu W. Wu)} and 林, {增熙(Tzeng H. Lin)} and 季, {匡華(Kwan H. Chi)} and 趙, {毅(Yee Chao)} and 黃, {以信(Y. S. Huang)} and 吳, {銘芳(Ming F. Wu)} and 陳, {育民(Yue M. Chen)} and 劉, {敏(Ming Liu)} and 彭汪, {嘉康(Jacqueline Whang-Peng)} and 李, {壽東(Shou D. Lee)} and 雷, {永耀(Wing Y. Lui)}",
year = "1994",
doi = "10.6316/TRO/199401",
language = "English",
volume = "1",
pages = "255--262",
journal = "放射治療與腫瘤學",
issn = "1023-988x",
publisher = "台灣放射腫瘤學會",
number = "3",

}

TY - JOUR

T1 - Cisplain, 5-Fluorouracil (5-FU), and Leucovorin(LV) in Refractory Gastric Cancer Patients

AU - 陳, 榮楷(Wing-K. Chan)

AU - 吳, 秋文(Chu W. Wu)

AU - 林, 增熙(Tzeng H. Lin)

AU - 季, 匡華(Kwan H. Chi)

AU - 趙, 毅(Yee Chao)

AU - 黃, 以信(Y. S. Huang)

AU - 吳, 銘芳(Ming F. Wu)

AU - 陳, 育民(Yue M. Chen)

AU - 劉, 敏(Ming Liu)

AU - 彭汪, 嘉康(Jacqueline Whang-Peng)

AU - 李, 壽東(Shou D. Lee)

AU - 雷, 永耀(Wing Y. Lui)

PY - 1994

Y1 - 1994

N2 - Background: Patients with advanced gastric cancer who failed first line chemotherapy have a poor prognosis. However, there are few effective treatments against refractory gastric cancer. Based on encouraging results of cisplatin, 5-Fluorouracil and leucovorin (PFL) in patients with gastric cancer, nasopharyngeal cancer and other cancers, we conducted this pilot study of test PEL chemotherapy in patients with refractory advanced gastric cancer.Method: Patients with measurable advanced gastric cancer, refractory to prior chemotherapy were eligible for study. Cisplatin 20mg/m^2/d, 5-FU 800mg/m^2/d and leucovorin 90mg/m^2/d were administered simultaneously by continuous 96-hour intravenous infusion every three weeks. Patients were evaluated for response, survival, and toxicity.Results: Twenty patients were studied. Fifteen patients were evaluable. There were no complete response. Partial response was achieved in 4 patients. The response rate of PFL chemotherapy were 27%. The overall toxicity was tolerable. Mucositis and leukopenia were the major toxicities. No grade IV toxicities or treatment-related deaths occurred.Conclusions: PEL chemotherpy is safe and may be effective in the treatment of refractory gastric cancer patients. Further clinical studies of PFL in gastric cancer may be indicated.

AB - Background: Patients with advanced gastric cancer who failed first line chemotherapy have a poor prognosis. However, there are few effective treatments against refractory gastric cancer. Based on encouraging results of cisplatin, 5-Fluorouracil and leucovorin (PFL) in patients with gastric cancer, nasopharyngeal cancer and other cancers, we conducted this pilot study of test PEL chemotherapy in patients with refractory advanced gastric cancer.Method: Patients with measurable advanced gastric cancer, refractory to prior chemotherapy were eligible for study. Cisplatin 20mg/m^2/d, 5-FU 800mg/m^2/d and leucovorin 90mg/m^2/d were administered simultaneously by continuous 96-hour intravenous infusion every three weeks. Patients were evaluated for response, survival, and toxicity.Results: Twenty patients were studied. Fifteen patients were evaluable. There were no complete response. Partial response was achieved in 4 patients. The response rate of PFL chemotherapy were 27%. The overall toxicity was tolerable. Mucositis and leukopenia were the major toxicities. No grade IV toxicities or treatment-related deaths occurred.Conclusions: PEL chemotherpy is safe and may be effective in the treatment of refractory gastric cancer patients. Further clinical studies of PFL in gastric cancer may be indicated.

KW - Cisplatin

KW - 5-Fluorouracil

KW - Leucovorin頑固性胃癌

KW - Refractory Gastric Cancer

KW - Fluorouracil

KW - Leucovorin

U2 - 10.6316/TRO/199401

DO - 10.6316/TRO/199401

M3 - Article

VL - 1

SP - 255

EP - 262

JO - 放射治療與腫瘤學

JF - 放射治療與腫瘤學

SN - 1023-988x

IS - 3

ER -